Viridian Therapeutics announces new CEO, $185M private placement, next-gen FcRn inhibitors

Viridian Therapeutics, Inc.\DE

Stephen Mahoney appointed President and CEO, succeeds Scott Myers. Base salary $650k, 55% bonus target, option for 1.26M shares.
$185M private placement: 8.79M shares at $12.38, plus 92,312 convertible preferred shares. Closing expected Nov 1, 2023.
Discloses preclinical FcRn inhibitors VRDN-006 and VRDN-008; first IND filing by year-end 2024. Targets autoimmune diseases.
TED pipeline: subcutaneous program selection by end 2023; VRDN-001 THRIVE Phase 3 active TED readout mid-2024.
Thomas Beetham appointed COO; base salary $500k, 45% bonus target, option for 474k shares.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stephen Mahoney

Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-10-30
Filed: October 30, 2023, 7:59 PM ET

Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

Appointed

Stephen Mahoney

President and Chief Executive Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-10-30
Filed: October 30, 2023, 7:59 PM ET

On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Mahoney was appointed as Director at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Director

Exact text from the filing

Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Mahoney was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viridian Therapeutics, Inc.\DE entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $185 million (effective 2023-10-30).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $185 million
Effective: 2023-10-30

Exact text from the filing

On October 30, 2023, Viridian Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).

View on SEC.gov

235 material agreements filed in the last 30 days. Browse all material agreements →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-265717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.